Del Rosso James Q
Dr. Del Rosso is with JDR Dermatology Research/Thomas Dermatology in Las Vegas, Nevada and Touro University Nevada in Henderson, Nevada.
J Clin Aesthet Dermatol. 2020 Feb;13(2):22-29. Epub 2020 Feb 1.
Topical corticosteroids (TCs) have played a central role, over the past several decades, as a treatment for many dermatologic disorders. A number of factors, including potency, anticipated efficacy, vehicle formulation, and patient preference, directly influence the success or failure of any TC. In this article, the author reviews and discusses the current literature on various aspects of TCs for the treatment of plaque psoriasis, including an overview of product selection tendencies of patients, conventional use and formulations of topical clobetasol propionate (CP) 0.05%, and the use of special additives (e.g., penetration enhancers) to increase CP potency. The author highlights data from recent studies that evaluated a new CP cream formulation that incorporates half the concentration of traditional CP (0.025%) without the loss of super-potency (Class I) status and without the use of traditional potency enhancement with propylene glycol.
在过去几十年里,外用皮质类固醇(TCs)在许多皮肤病的治疗中发挥了核心作用。包括效力、预期疗效、剂型以及患者偏好等在内的诸多因素,直接影响着任何一种外用皮质类固醇治疗的成败。在本文中,作者回顾并讨论了关于外用皮质类固醇治疗斑块状银屑病各方面的当前文献,包括患者的产品选择倾向概述、0.05%丙酸氯倍他索(CP)的常规使用和剂型,以及使用特殊添加剂(如渗透促进剂)来增强CP的效力。作者强调了近期研究的数据,这些研究评估了一种新的CP乳膏剂型,其传统CP浓度减半(0.025%),却不失超强效(I类)地位,且未使用丙二醇来传统增强效力。